Compare GSK plc (GSK) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs New York Times Co — how do they compare? GSK plc trades at $52.65 (market cap $101.34B), while New York Times Co trades at $75.66 (market cap $12.18B). The key difference: GSK plc is far larger — about 8.3× New York Times Co's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | NYT | |
|---|---|---|
Market Cap | $101.34B | $12.18B |
Sector | Health | Media |
52-Week High | $61.18 | $85.86 |
52-Week Low | $36.20 | $51.43 |
Enterprise Value | $121.95B | $11.57B |
Dividend Yield | 3.49% | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
The New York Times (NYT) trades at $72.98, down 2.75% today, with a neutral technical outlook and mixed analyst sentiment. Fundamentally, the company shows strong profitability with 51.12% gross margins and consistent earnings beats, though valuation multiples appear elevated. Recent news highlights legal challenges involving reporter subpoenas and ongoing copyright disputes with OpenAI.
Outlook remains cautiously optimistic with a $78 consensus price target representing 7% upside potential. Key opportunities include sustained digital subscription growth and margin expansion, while risks involve legal uncertainties and potential regulatory pressures. The stock offers defensive characteristics amid market volatility but faces near-term headwinds from legal proceedings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
